{"DataElement":{"publicId":"7060446","version":"1","preferredName":"Antihypertensive Agent Administered Name","preferredDefinition":"The name of the antihypertensive agent, a drug used in the treatment of acute or chronic elevation in blood pressure regardless of pharmacological mechanism, administered to the patient.","longName":"2762695v1.0:7060434v1.0","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"2762695","version":"1","preferredName":"Antihypertensive Agent Administered","preferredDefinition":"information related to an antihypertensive, a drug used in the treatment of acute or chronic elevation in blood pressure regardless of pharmacological mechanism, being administered.","longName":"ANTIHYPAGT_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2762691","version":"1","preferredName":"Antihypertensive Agent","preferredDefinition":"Drugs used in the treatment of acute or chronic hypertension regardless of pharmacological mechanism. Among the antihypertensive agents are diuretics, adrenergic beta-antagonists; andrenergic alpha-antogonists; angiotensin-converting enzyme inhibitors; calcium channel blockers; ganglionic blockers; and vasodilator agents. (MeSH)","longName":"C270","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antihypertensive Agent","conceptCode":"C270","definition":"Any substance used in the treatment of acute or chronic hypertension regardless of pharmacological mechanism. Antihypertensive agents include diuretics, alpha-adrenergic and beta-adrenergic antagonists, angiotensin-converting enzyme inhibitors, calcium channel blockers, ganglionic blockers, and vasodilator agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"511062E6-14D2-2A99-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-07-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-07-02","modifiedBy":"ONEDATA","dateModified":"2008-07-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"510F92D3-F4C7-31A4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-31","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-07-02","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7060434","version":"1","preferredName":"Antihypertensive Agent Administered Name","preferredDefinition":"The name of the administered antihypertensive agent.","longName":"7060434v1.0","context":"Alliance","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Phenoxybenzamine","valueDescription":"Phenoxybenzamine","ValueMeaning":{"publicId":"7060436","version":"1","preferredName":"Phenoxybenzamine","longName":"7060436","preferredDefinition":"A synthetic, dibenzamine alpha adrenergic antagonist with antihypertensive and vasodilatory properties. Phenoxybenzamine non-selectively and irreversibly blocks the postsynaptic alpha-adrenergic receptor in smooth muscle, thereby preventing vasoconstriction, relieving vasospasms, and decreasing peripheral resistance. Reflex tachycardia may occur and may be enhanced by blockade of alpha-2 receptors which enhances norepinephrine release. Phenoxybenzamine is reasonably anticipated to be a human carcinogen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phenoxybenzamine","conceptCode":"C62065","definition":"A synthetic, dibenzamine alpha adrenergic antagonist with antihypertensive and vasodilatory properties. Phenoxybenzamine non-selectively and irreversibly blocks the postsynaptic alpha-adrenergic receptor in smooth muscle, thereby preventing vasoconstriction, relieving vasospasms, and decreasing peripheral resistance. Reflex tachycardia may occur and may be enhanced by blockade of alpha-2 receptors which enhances norepinephrine release. Phenoxybenzamine is reasonably anticipated to be a human carcinogen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A00723-661A-558A-E053-F662850A380C","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A00723-6633-558A-E053-F662850A380C","beginDate":"2019-11-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Doxazosin","valueDescription":"Doxazosin","ValueMeaning":{"publicId":"2830038","version":"1","preferredName":"Doxazosin","longName":"2830038","preferredDefinition":"A quinazoline with antihypertensive and antineoplastic properties. Doxazosin is an alpha-adrenergic antagonist that selectively inhibits alpha-1 adrenergic receptors. Blockages of the alpha-1 adrenergic action on the vascular smooth muscles lead to a decrease in vascular resistance and antihypertensive activity. This agent also shows high affinity to alpha-1c adrenoceptor, the predominant functional type in the prostate, which may partially attribute to its effect in treatment of benign prostatic hyperplasia. Furthermore, doxazosin induces apoptosis in prostate cancer cells mediated through inhibition of protein kinase B (PKB)/Akt-signaling death receptor regulatory pathway.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxazosin","conceptCode":"C61737","definition":"A quinazoline with antihypertensive and antineoplastic properties. Doxazosin is an alpha-adrenergic antagonist that selectively inhibits alpha-1 adrenergic receptors. Blockages of the alpha-1 adrenergic action on the vascular smooth muscles lead to a decrease in vascular resistance and antihypertensive activity. This agent also shows high affinity to alpha-1c adrenoceptor, the predominant functional type in the prostate, which may partially attribute to its effect in treatment of benign prostatic hyperplasia. Furthermore, doxazosin induces apoptosis in prostate cancer cells mediated through inhibition of protein kinase B (PKB)/Akt-signaling death receptor regulatory pathway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6191B569-533B-B3A2-E040-BB89AD4312A4","latestVersionIndicator":"Yes","beginDate":"2009-01-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-01-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A00723-663D-558A-E053-F662850A380C","beginDate":"2019-11-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Terazosin","valueDescription":"Terazosin","ValueMeaning":{"publicId":"7060438","version":"1","preferredName":"Terazosin","longName":"7060438","preferredDefinition":"A drug used to treat urinary problems caused by an enlarged prostate. It is also used to treat high blood pressure and is being studied in the treatment of other conditions. Terazosin relaxes muscle tissue in blood vessels and in the prostate. It is a type of alpha blocker.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Terazosin","conceptCode":"C61964","definition":"A drug used to treat urinary problems caused by an enlarged prostate. It is also used to treat high blood pressure and is being studied in the treatment of other conditions. Terazosin relaxes muscle tissue in blood vessels and in the prostate. It is a type of alpha blocker.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A00723-664A-558A-E053-F662850A380C","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A00723-6663-558A-E053-F662850A380C","beginDate":"2019-11-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Prazosin","valueDescription":"Prazosin","ValueMeaning":{"publicId":"7060440","version":"1","preferredName":"Prazosin","longName":"7060440","preferredDefinition":"A synthetic piperazine derivative and an alpha-1 adrenergic receptor inhibitor used primarily as an anti-hypertensive. Prazosin's effects are most pronounced in the large resistance vessels (i.e. arterioles) and result in a decrease in total systemic vascular resistance (SVR) without a rebound or reflex tachycardia. To a lesser extent, this agent also decreases the tone of the bladder sphincter, thereby allowing the opening of the bladder into the urethra and thus relieving the urinary conditions associated with benign prostatic hypertrophy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prazosin","conceptCode":"C767","definition":"A synthetic piperazine derivative and an alpha-1 adrenergic receptor inhibitor used primarily as an anti-hypertensive. Prazosin's effects are most pronounced in the large resistance vessels (i.e. arterioles) and result in a decrease in total systemic vascular resistance (SVR) without a rebound or reflex tachycardia. To a lesser extent, this agent also decreases the tone of the bladder sphincter, thereby allowing the opening of the bladder into the urethra and thus relieving the urinary conditions associated with benign prostatic hypertrophy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A00723-6670-558A-E053-F662850A380C","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A00723-6689-558A-E053-F662850A380C","beginDate":"2019-11-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Atenolol","valueDescription":"Atenolol","ValueMeaning":{"publicId":"2577685","version":"1","preferredName":"Atenolol","longName":"2577685","preferredDefinition":"A synthetic isopropylamino-propanol derivative used as an antihypertensive, hypotensive and antiarrhythmic Atenolol acts as a peripheral, cardioselective beta blocker specific for beta1-receptors, without intrinsic sympathomimetic effects. It reduces exercise heart rates and delays atrioventricular conduction, with overall oxygen requirements decreasing. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atenolol","conceptCode":"C28836","definition":"A synthetic isopropylamino-propanol derivative used as an antihypertensive, hypotensive and antiarrhythmic Atenolol acts as a peripheral, cardioselective beta blocker specific for beta-1 adrenergic receptors, without intrinsic sympathomimetic effects. It reduces exercise heart rates and delays atrioventricular conduction, with overall oxygen requirements decreasing. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FC82-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A00723-6693-558A-E053-F662850A380C","beginDate":"2019-11-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Metoprolol","valueDescription":"Metoprolol","ValueMeaning":{"publicId":"7060442","version":"1","preferredName":"Metoprolol","longName":"7060442","preferredDefinition":"A cardioselective competitive beta-1 adrenergic receptor antagonist with antihypertensive properties and devoid of intrinsic sympathomimetic activity. Metoprolol antagonizes beta 1-adrenergic receptors in the myocardium, thereby reducing the rate and force of myocardial contraction leading to a reduction in cardiac output. This agent may also reduce the secretion of renin with subsequent reduction in levels of angiotensin II thereby preventing vasoconstriction and aldosterone secretion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metoprolol","conceptCode":"C61845","definition":"A cardioselective competitive beta-1 adrenergic receptor antagonist with antihypertensive properties and devoid of intrinsic sympathomimetic activity. Metoprolol antagonizes beta 1-adrenergic receptors in the myocardium, thereby reducing the rate and force of myocardial contraction leading to a reduction in cardiac output. This agent may also reduce the secretion of renin with subsequent reduction in levels of angiotensin II thereby preventing vasoconstriction and aldosterone secretion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A00723-66A0-558A-E053-F662850A380C","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A00723-66B9-558A-E053-F662850A380C","beginDate":"2019-11-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Propranolol","valueDescription":"Propranolol","ValueMeaning":{"publicId":"7060444","version":"1","preferredName":"Propranolol","longName":"7060444","preferredDefinition":"A synthetic, nonselective beta-adrenergic receptor blocker with antianginal, antiarrhythmic, antihypertensive properties. Propranolol competitively antagonizes beta-adrenergic receptors, thereby causing negative chronotropic and inotropic effects leading to a reduction in cardiac output.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Propranolol","conceptCode":"C62073","definition":"A synthetic, nonselective beta-adrenergic receptor blocker with antianginal, antiarrhythmic, antihypertensive properties. Propranolol competitively antagonizes beta-adrenergic receptors, thereby causing negative chronotropic and inotropic effects leading to a reduction in cardiac output.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A00723-66C6-558A-E053-F662850A380C","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A00723-66DF-558A-E053-F662850A380C","beginDate":"2019-11-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Amlodipine","valueDescription":"Amlodipine","ValueMeaning":{"publicId":"7060445","version":"1","preferredName":"Amlodipine","longName":"7060445","preferredDefinition":"A synthetic dihydropyridine and a calcium channel blocker with antihypertensive and antianginal properties. Amlodipine inhibits the influx of extracellular calcium ions into myocardial and peripheral vascular smooth muscle cells, thereby preventing vascular and myocardial contraction. This results in a dilatation of the main coronary and systemic arteries, decreased myocardial contractility, increased blood flow and oxygen delivery to the myocardial tissue, and decreased total peripheral resistance. This agent may also modulate multi-drug response (MDR) activity through inhibition of the p-glycoprotein efflux pump.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amlodipine","conceptCode":"C61635","definition":"A synthetic dihydropyridine and a calcium channel blocker with antihypertensive and antianginal properties. Amlodipine inhibits the influx of extracellular calcium ions into myocardial and peripheral vascular smooth muscle cells, thereby preventing vascular and myocardial contraction. This results in a dilatation of the main coronary and systemic arteries, decreased myocardial contractility, increased blood flow and oxygen delivery to the myocardial tissue, and decreased total peripheral resistance. This agent may also modulate multi-drug resistance (MDR) activity through inhibition of the p-glycoprotein efflux pump.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A00723-66EB-558A-E053-F662850A380C","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A00723-6704-558A-E053-F662850A380C","beginDate":"2019-11-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Verapamil","valueDescription":"Verapamil","ValueMeaning":{"publicId":"3128735","version":"1","preferredName":"Verapamil","longName":"3128735","preferredDefinition":"A phenylalkylamine calcium channel blocking agent. Verapamil inhibits the transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility.  This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Verapamil","conceptCode":"C928","definition":"A phenylalkylamine calcium channel blocking agent. Verapamil inhibits the transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility.  This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1DCB-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A00723-670E-558A-E053-F662850A380C","beginDate":"2019-11-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Nitroglycerin","valueDescription":"Nitroglycerin","ValueMeaning":{"publicId":"3335138","version":"1","preferredName":"Nitroglycerin","longName":"3335138","preferredDefinition":"An organic nitrate with vasodilator activity. Nitroglycerin is converted into nitric oxide (NO) in smooth muscle and activates guanylyl cyclase, thereby increasing cGMP concentration, and resulting in smooth muscle relaxation. Dilatation of the veins results in decreased venous return to the heart, thereby decreasing left ventricular volume (reduced preload) and decreasing myocardial oxygen requirements. Arteriolar relaxation reduces arteriolar resistance (reduced afterload), thereby decreasing myocardial oxygen demands. In addition, nitroglycerine causes coronary artery dilatation, thereby improving myocardial blood distribution.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nitroglycerin","conceptCode":"C29294","definition":"An organic nitrate with vasodilator activity. Nitroglycerin is converted into nitric oxide (NO) in smooth muscle and activates guanylyl cyclase, thereby increasing cGMP concentration, and resulting in smooth muscle relaxation. Dilatation of the veins results in decreased venous return to the heart, thereby decreasing left ventricular volume (reduced preload) and decreasing myocardial oxygen requirements. Arteriolar relaxation reduces arteriolar resistance (reduced afterload), thereby decreasing myocardial oxygen demands. In addition, nitroglycerine causes coronary artery dilatation, thereby improving myocardial blood distribution.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43BE7C1-ED10-6A5C-E040-BB89AD437808","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A00723-6718-558A-E053-F662850A380C","beginDate":"2019-11-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Isosorbide mononitrate","valueDescription":"Isosorbide Mononitrate","ValueMeaning":{"publicId":"3282733","version":"1","preferredName":"Isosorbide Mononitrate","longName":"3282733","preferredDefinition":"The mononitrate salt form of isosorbide, an organic nitrate with vasodilator activity. Isosorbide mononitrate relaxes vascular smooth muscle by formation of the free radical nitric oxide (NO), which is identical to the endothelium-derived relaxing factor (EDRF). NO activates guanylyl cyclase, thereby increasing the synthesis of cGMP within smooth muscle, resulting in dephosphorylation of light chain myosin and relaxation of peripheral arteries and veins. In addition, isosorbide mononitrate relaxes coronary arteries, thereby increasing the blood circulation through the ischemic area. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Isosorbide Mononitrate","conceptCode":"C47575","definition":"The mononitrate salt form of isosorbide, an organic nitrate with vasodilator activity. Isosorbide mononitrate relaxes vascular smooth muscle by formation of the free radical nitric oxide (NO), which is identical to the endothelium-derived relaxing factor (EDRF). NO activates guanylyl cyclase, thereby increasing the synthesis of cGMP within smooth muscle, resulting in dephosphorylation of light chain myosin and relaxation of peripheral arteries and veins. In addition, isosorbide mononitrate relaxes coronary arteries, thereby increasing the blood circulation through the ischemic area. (NCI05)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD7A5918-D78E-456E-E040-BB89AD433590","latestVersionIndicator":"Yes","beginDate":"2011-09-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A00723-672C-558A-E053-F662850A380C","beginDate":"2019-11-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Isosorbide dinitrate","valueDescription":"Isosorbide Dinitrate","ValueMeaning":{"publicId":"2578205","version":"1","preferredName":"Isosorbide Dinitrate","longName":"2578205","preferredDefinition":"The dinitrate salt form of isosorbide, an organic nitrate with vasodilator activity. Isosorbide dinitrate relaxes vascular smooth muscle by formation of the free radical nitric oxide (NO), which is identical to the endothelium-derived relaxing factor (EDRF). NO activates guanylyl cyclase, thereby increasing the synthesis of cGMP within smooth muscle, resulting in dephosphorylation of light chain myosin and relaxation of peripheral arteries and veins. In addition, isosorbide dinitrate relaxes coronary arteries, thereby increasing the blood circulation through the ischemic area. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Isosorbide Dinitrate","conceptCode":"C29134","definition":"The dinitrate salt form of isosorbide, an organic nitrate with vasodilator activity. Isosorbide dinitrate relaxes vascular smooth muscle by formation of the free radical nitric oxide (NO), which is identical to the endothelium-derived relaxing factor (EDRF). NO activates guanylyl cyclase, thereby increasing the synthesis of cGMP within smooth muscle, resulting in dephosphorylation of light chain myosin and relaxation of peripheral arteries and veins. In addition, isosorbide dinitrate relaxes coronary arteries, thereby increasing the blood circulation through the ischemic area. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE8A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A00723-6740-558A-E053-F662850A380C","beginDate":"2019-11-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Metyrosine","valueDescription":"Metyrosine","ValueMeaning":{"publicId":"3434558","version":"1","preferredName":"Metyrosine","longName":"3434558","preferredDefinition":"A methylated tyrosine, a catecholamine synthesis antagonist with antihypertensive property. Metyrosine competitively inhibits tyrosine 3-monooxygenase, an enzyme that activates molecular oxygen to catalyze the hydroxylation of tyrosine to dihydroxyphenylalanine (Dopa), an intermediate to catecholamine (dopamine, norepinephrine, and epinephrine) production. This agent reduces the elevated levels of catecholamines associated with pheochromocytoma, thereby preventing hypertension.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metyrosine","conceptCode":"C998","definition":"A methylated tyrosine, a catecholamine synthesis antagonist with antihypertensive property. Metyrosine competitively inhibits tyrosine 3-monooxygenase, an enzyme that activates molecular oxygen to catalyze the hydroxylation of tyrosine to dihydroxyphenylalanine (Dopa), an intermediate to catecholamine (dopamine, norepinephrine, and epinephrine) production. This agent reduces the elevated levels of catecholamines associated with pheochromocytoma, thereby preventing hypertension.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD3F6081-6556-1C16-E040-BB89AD431E82","latestVersionIndicator":"Yes","beginDate":"2012-04-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A00723-674A-558A-E053-F662850A380C","beginDate":"2019-11-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"6424136","version":"1","preferredName":"Other","longName":"6424136","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"753441A1-068C-5A23-E053-F662850A6B7A","latestVersionIndicator":"Yes","beginDate":"2018-09-06","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-02-02","changeDescription":null,"administrativeNotes":"2023.2.2 Alt VM added per ticket request CADSR0002006. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A00723-6754-558A-E053-F662850A380C","beginDate":"2019-11-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2229718","version":"1","preferredName":"Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F6EF4E2B-76AE-72C1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-05-16","modifiedBy":"ONEDATA","dateModified":"2005-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A00723-6601-558A-E053-F662850A380C","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-11-18","modifiedBy":"MORENOC","dateModified":"2020-03-05","changeDescription":"3/5/2020: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Agent name","type":"Preferred Question Text","description":"Agent name","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A04FA6-FACE-723B-E053-F662850A55A5","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-11-18","modifiedBy":"MORENOC","dateModified":"2020-03-05","changeDescription":"3/5/2020: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}